ArticleFrontiers in oncology2025
Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a deadly and highly metastatic malignancy; the liver is the most frequent site of metastasis (70-80%), however, bone metastases are rare, occurring in approximately 5% of cases. Currently, there are no documented reports of effective responses to therapy for bone metastases, especially in the context of cell-based treatments. Here, we report the first case of a partial response according to RECIST v1.1, with a reduction in size and dissolution of liver and bone metastases from pancreatic cancer, for the novel cell therapy, SL-28, under the expanded access pathway (NCT06872489). SL-28 (Leukocyte-Tells) is a novel cell therapy that uses allogeneic leukocytes, whose anticancer activity is increased
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.